Abstract
Nesfatin-1 is an eighty two amino acid, naturally occurring multifunctional protein encoded in the precursor nucleobindin-2 (NUCB2). A comparison of sequences indicates that NUCB2 is present in a number of animals, from hydra to humans. The 30 amino acid mid-segment of nesfatin-1 is considered to be the bioactive core of the protein, and this region displays the highest identity among nesfatin-1 sequences reported thus far. Similar to the sequence relationships observed, the tissue-specific expression and biological actions of nesfatin-1 also appear to be highly conserved across species. For example, brain is a major tissue abundantly expressing nesfatin- 1 in several species. It has been shown that various key regions of the rat, mouse and goldfish brain, which are involved in the regulation of feeding and metabolism express nesfatin-1. Exogenous administration of nesfatin-1 results in a decrease in the food intake of rats, mice and goldfish. In addition, nesfatin-1 has been shown to regulate a number of other physiological processes including hormone secretion from the pancreatic islets and pituitary gland, stress and behavior. While nesfatin-1 research still remains an emerging area in physiology, the literature available thus far clearly shows that nesfatin-1 is an important regulator of homeostasis in animals.
Keywords: Food intake, metabolism, brain, pancreas, fish, rats, mice, humans.
Current Pharmaceutical Design
Title:Phylogenetic Aspects of Nucleobindin-2/Nesfatin-1
Volume: 19 Issue: 39
Author(s): Haneesha Mohan and Suraj Unniappan
Affiliation:
Keywords: Food intake, metabolism, brain, pancreas, fish, rats, mice, humans.
Abstract: Nesfatin-1 is an eighty two amino acid, naturally occurring multifunctional protein encoded in the precursor nucleobindin-2 (NUCB2). A comparison of sequences indicates that NUCB2 is present in a number of animals, from hydra to humans. The 30 amino acid mid-segment of nesfatin-1 is considered to be the bioactive core of the protein, and this region displays the highest identity among nesfatin-1 sequences reported thus far. Similar to the sequence relationships observed, the tissue-specific expression and biological actions of nesfatin-1 also appear to be highly conserved across species. For example, brain is a major tissue abundantly expressing nesfatin- 1 in several species. It has been shown that various key regions of the rat, mouse and goldfish brain, which are involved in the regulation of feeding and metabolism express nesfatin-1. Exogenous administration of nesfatin-1 results in a decrease in the food intake of rats, mice and goldfish. In addition, nesfatin-1 has been shown to regulate a number of other physiological processes including hormone secretion from the pancreatic islets and pituitary gland, stress and behavior. While nesfatin-1 research still remains an emerging area in physiology, the literature available thus far clearly shows that nesfatin-1 is an important regulator of homeostasis in animals.
Export Options
About this article
Cite this article as:
Mohan Haneesha and Unniappan Suraj, Phylogenetic Aspects of Nucleobindin-2/Nesfatin-1, Current Pharmaceutical Design 2013; 19 (39) . https://dx.doi.org/10.2174/138161281939131127124149
DOI https://dx.doi.org/10.2174/138161281939131127124149 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances in the Discovery of Tissue Factor/Factor VIIa Inhibitors and Dual Inhibitors of Factor VIIa/Factor Xa
Current Pharmaceutical Design Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?
Current Vascular Pharmacology Adverse Bioeffects of Ultrasound Contrast Agents Used in Echocardiography: True Safety Issue or “Much Ado About Nothing”?
Current Vascular Pharmacology Diabetic Retinopathy, Superoxide Damage and Antioxidants
Current Pharmaceutical Biotechnology Autophagy Inhibition Rescues Against Leptin-Induced Cardiac Contractile Dysfunction
Current Pharmaceutical Design Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research Alert Cell Strategy: Mechanisms of Inflammatory Response and Organ Protection
Current Pharmaceutical Design Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Is Nitric Oxide Assuming a Janus-Face in The Central Nervous System?
Current Medicinal Chemistry Modulation of Individual Susceptibility to the No-Reflow Phenomenon after Acute Myocardial Infarction
Current Pharmaceutical Design Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Clinical Thiazolidinediones as PPARγ Ligands with the Potential for the Prevention of Cardiovascular Disease in Diabetes
Current Diabetes Reviews Development of Monoclonal Antibodies that Inhibit Platelet Adhesion or Aggregation as Potential Anti-Thrombotic Drugs
Cardiovascular & Hematological Disorders-Drug Targets Human Adipose-Derived Stem Cells Delay Retinal Degeneration in Royal College of Surgeons Rats Through Anti-Apoptotic and VEGF-Mediated Neuroprotective Effects
Current Molecular Medicine Targeting STAT1 in Both Cancer and Insulin Resistance Diseases
Current Protein & Peptide Science Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry Pathophysiology of Ischemic Stroke: Role of Oxidative Stress
Current Pharmaceutical Design